VEGF, HIF-1 α The Relationship between Angiogenesis and Biological Behavior in Epithelial Ovarian Cancer

Abstract

Abstract: Objective To detect the expression of VEGF, HIF-1α and MVD in EOC and normal ovarian tissues and their relationship with prognosis. Methods The clinical data of 46 EOC patients were retrospectively analyzed to investigate the relationship between the clinicopathological characteristics and the expression of VEGF, HIF-1α and MVD. Immunohistochemistry was performed to measure VEGF, HIF-1α expression in normal ovarian tissues and EOCs,and MVD was determined by using immunostaining of CD34. The survival analysis was performed by using Kaplan-Meier method to determine whether the expression of VEGF, HIF-1α and MVD was associated with the overall survival of EOC patients. Results The expression of VEGF, HIF-1α and MVD in EOC tissues were correlated with FIGO stage, pathological grade and lymph node metastasis(P<0.05), but not with age or histological subtype（P>0.05）. The expressions of VEGF, HIF-1α and MVD in EOC tissues were significantly higher than those in normal ovarian tissues(P<0.05). The overall survival probability of high group of VEGF, HIF-1α and MVD was significantly lower than those of the low group(P<0.05). Conclusion Angiogenesis is closely related to the growth, metastasis and prognosis of EOC, and the expression of VEGF and MVD can be used as indicators of EOC angiogenesis. Hypoxic microenvironment plays an important role in the process of tumor angiogenesis, progression and metastasis. Tumor growth-dependent factors such as VEGF and HIF-1α are expected to become new targets for tumor therapy. Molecular biological targeted therapy targeting HIF-1α or hypoxic microenvironment may bring new hope for the treatment of advanced malignant tumors and thereby improve the prognosis of patients.

Key words: VEGF, angiogenesis, HIF-1α, epithelial ovarian cancer

CLC Number:

R711.75

WANG Wen, MA Jun-xia, CUI Xiu-juan, TIAN Xiang-yu. VEGF, HIF-1 α The Relationship between Angiogenesis and Biological Behavior in Epithelial Ovarian Cancer[J]. ZHONGHUA YANGSHENG BAOJIAN, 2023, 41(20): 10-13.

References

[1] MURPHY A D, MORGAN R D, CLAMP A R, et al.The role of vascular endothelial growth factor inhibitors in the treatment of epithelial ovarian cancer[J]. Br J Cancer,2022,126(6):851-864.
[2] RÜEGG C, DORMOND O, MARIOTTI A. Endothelial cell integrins and COX-2: mediators and therapeutic targets of tumor angiogenesis[J]. Biochim Biophys Acta,2004,1654(1):51-67.
[3] WANG X, DU Z W, XU T M, et al.HIF-1α Is a Rational Target for Future Ovarian Cancer Therapies[J]. Front Oncol,2021,11:785111.
[4] LIM D, DO Y, KWON B S, et al.Angiogenesis and vasculogenic mimicry as therapeutic targets in ovarian cancer[J]. BMB Rep,2020,53(6):291-298.
[5] WANG Y, LI B X, LI X.Identification and Validation of Angiogenesis-Related Gene Expression for Predicting Prognosis in Patients With Ovarian Cancer[J]. Front Oncol,2022,11:783666.
[6] YOU L, WU W, WANG X, et al .The role of hypoxia-inducible factor 1 in tumor immune evasion[J]. Med Res Rev,2021,41(3): 1622-1643.
[7] KURMAN R J, CARCANGIU M L, HERRINGTON C S, et al. WHO Classilication of Tumours of Female Reproductive Organs[M].2014, 4th edition, International Agency for Research on Cancer (IARC).
[8] SUN J, SHA B, ZHOU W, et al.VEGF-mediated angiogenesis stimulates neural stem cell proliferation and differentiation in the premature brain[J]. Biochem Biophys Res Commun,2010,394(1):146-152.
[9] TANG H S,FENG Y J,YAO L Q.Angiogenesis, vasculogenesis, andvasculogenic mimicry in ovarian cancer[J]. International Journal ofGynecological Cancer,2009,19(4):605-610.
[10] PE'ER J, SHWEIKI D, LTIN A, et al. Hypoxia-induced expression of vascular endo-thelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases[J]. Lab Invest,1995,72(6):638-645.
[11] SILINS G, GRIMMOND S, EGERTON M, et al.Analysis of the promoter region of the human VEGF-related factor gene[J]. Biochem Biophys Res Commun,1997, 230(2):413-418.
[12] FORSYTHE J A, JIANG B H, LYER N V, et al.Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1[J]. Mol Cell Biol,1996,16(9):4604-4613.
[13] MANIOTIS A J, FOLBERG R, HESS A, et al.Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry[J]. Am J Pathol,1999,155(3):739-752.
[14] FAN Y, CHENG H, LIU Y, et al.Metformin anticancer: Reverses tumor hypoxia induced by bevacizumab and reduces the expression of cancer stem cell markers CD44/CD117 in human ovarian cancer SKOV3 cells[J]. Front Pharmacol,2022,13:955984.
[15] OLALEKAN S, XIE B, BACK R, et al.Characterizing the tumor microenvironment of metastatic ovarian cancer by single-cell transcriptomics[J]. Cell Rep,2021,35(8):109165.
[16] ZHANG Q L, DING J S, WANG Y M, et al.Tumor microenvironment manipulates chemoresistance in ovarian cancer (Review)[J]. Oncol Rep,2022,47(5):102.
[17] Almeida-Nunes DL, Mendes-Frias AM, Silvestre R, et al.Immune Tumor Microenvironment in Ovarian Cancer Ascites[J]. Int J Mol Sci,2022,23(18):10692.
[18] SALINAS-VERA Y M, GALLARDO-RINCÓN D, RUÍZ-GARCÍA E, et al. The Role of Hypoxia in Endometrial Cancer[J]. Curr Pharm Biotechnol,2022,23(2):221-234.
[19] KLEMBA A, BODNAR L, WAS H, et al.Hypoxia-Mediated Decrease of Ovarian Cancer Cells Reaction to Treatment: Significance for Chemo-and Immunotherapies[J]. Int J Mol Sci,2020,21(24):9492.